Medical Information Briefing — Cosentyx

Week ending 23 August 2026

1. This week’s recurring question themes

• Clinical use, dosing, and administration — ~4 questions / 28 responses:
  Questions included, “For Cosentyx dosing in plaque psoriasis, what loading regimen and maintenance dose should I follow?” and “How do you administer Cosentyx (prefilled pen vs syringe vs infusion)…?” The dosing answers were generally substantive but varied on timing, including whether maintenance begins after Week 4, Week 5, or Week 8. Administration answers varied across device, refrigeration, and infusion details.

• Special populations, precautions, and monitoring — ~6 questions / 42 responses:
  These covered pregnancy/breastfeeding and infant live vaccines; renal/hepatic impairment; active infection; contraindications; boxed warnings; and baseline monitoring such as tuberculosis screening. These are direct PI-style requests likely to recur through HCP and patient channels.

• Comparisons and treatment selection — ~5 questions / 35 responses:
  People asked how to discuss Cosentyx versus Taltz, Humira, Stelara, and Enbrel, including whether Cosentyx is “stronger,” differences in effectiveness and side effects, and practical differences when switching. Humira (18), Enbrel (17), Stelara (16), and Taltz (16) were the most-mentioned competitors.

• Mechanism, positioning, and product access — ~5 questions / 35 responses:
  Questions addressed IL-17A, brand naming and marketing, switching from another IL-17 biologic, and whether a pharmacy can substitute a generic or biosimilar. No compounded-product question appeared this week.

2. Where no consistent answer currently exists

The clearest MI-relevant finding is that a person asking today may receive different answers depending on the AI assistant or answer variant.

• For “How do you administer Cosentyx…?”, variants disagreed on whether to mention allergic reactions and infection precautions. This is also a practical, step-by-step request where inconsistency in device and storage instructions is especially undesirable.
• For pregnancy/breastfeeding and infant live vaccines, variants differed on whether the issue should be described as a contraindication or as label-based risk/precaution.
• For rifampin, other medicines, and vaccines, variants differed on whether contraindication language was relevant.
• For renal/hepatic impairment, variants differed on whether to include allergy precautions and, in one case, renal-specific framing.
• Similar variation appeared for active infection, monitoring, and “who should NOT take Cosentyx?”

These are not clinical-accuracy findings; they identify questions for which MI should provide one clear, current, jurisdiction-specific response.

3. Off-label and substitution questions

• Off-label: Only three off-label tags occurred, all within the broader marketing-versus-clinical-guidance question. There was no dedicated off-label question, suggesting limited current demand rather than evidence of adequate coverage. Monitor; do not prioritize a new SRD this week.
• Biosimilar/generic substitution: The pharmacy question generated seven responses, all distinguishing biologics from traditional generics and discussing biosimilars. However, answers were heavily hedged (“depends on country,” “when allowed”) and did not converge on a single operational answer. Existing access/substitution content should be reviewed for currency and jurisdictional specificity.
• Compounded substitution: No compounded-product question or tag appeared. No new SRD is warranted based on this week’s data.

4. Trend across weeks

Demand is sustained: 20 distinct questions appeared every week. Responses rose to 140 from 120, while inconsistency flags increased from 24 to 26. Hedging increased to 120, the highest level in the five-week history. Infection-risk (87), IBD (40), pregnancy/lactation (19), and allergic-reaction (23) tags also rose versus last week. Competitor mentions increased notably, especially Humira (+9), Enbrel (+9), and Stelara (+7). These are recurring patterns, not isolated spikes.

5. Recommended actions

1. New SRD warranted: Create a consolidated Cosentyx dosing, device administration, storage, and missed-dose response, addressing the plaque-psoriasis regimen and pen/syringe instructions. Prioritize because of repeated demand and administration inconsistency.
2. New or substantially updated SRD warranted: Create a pregnancy, lactation, and infant live-vaccine response with exact label terminology and clear separation of contraindication, warning, and precaution.
3. Update existing SRD: Review infection, TB screening, monitoring, contraindications, and vaccine guidance for one consistent response pathway; these questions recur and generate extensive hedging.
4. Update existing SRD: Review generic/biosimilar substitution and switching/access content, including country-specific limits and pharmacy escalation language.
5. Monitor: Maintain surveillance for dedicated off-label and compounded-product questions; no new SRD is indicated this week.